biostudies-literatureChen RFundamental Research Funds for the Central UniversitiesGuangzhou Basic and Applied Basic Research ProgramSpecial Research and Development Program of GuangzhouImportant Key Program of Natural Science Foundation of ChinaPearl River S and T Nova Program of GuangzhouSpecial 2019-nCoV Program of NSFCNational Natural Science Foundation of ChinaHigh-level Biosafety Laboratory Construction Program of the Science and Technology Projects of Guangdong Province of ChinaEmergency Key Program of Guangzhou LaboratoryExchange Program of NSFCShenzhen Science and Technology Programe2105378https://www.ebi.ac.uk/biostudies/studies/S-EPMC9008796biostudies-literatureUnknown9(11)The SARS-CoV-2 Delta (B.1.617.2) strain is a variant of concern (VOC) that has become the dominant strain worldwide in 2021. Its transmission capacity is approximately twice that of the original strain, with a shorter incubation period and higher viral load during infection. Importantly, the breakthrough infections of the Delta variant have continued to emerge in the first-generation vaccine recipients. There is thus an urgent need to develop a novel vaccine with SARS-CoV-2 variants as the major target. Here, receptor binding domain (RBD)-conjugated nanoparticle vaccines targeting the Delta variant, as well as the early and Beta/Gamma strains, are developed. Under both a single-dose and a prime-boost strategy, these RBD-conjugated nanoparticle vaccines induce the abundant neutralizing antiAdvanced science (Weinheim, Baden-Wurttemberg, Germany)Development of Receptor Binding Domain (RBD)-Conjugated Nanoparticle Vaccines with Broad Neutralization against SARS-CoV-2 Delta and Other Variants.PMC90087962018060101182021B1212030012321007438215071055382041002JCYJ20200109142601702202102021094EKPG21-2492169201819719182021020210582020080700102021qntd43JSGG202002251504314728173006082171825Peng YZhang HDeng JWu BDeng KWang GLin YZou FLiang CWu SLiang LWang XChen RDeng XYuan YZhou MXi ZLi CPan TLi RLi YBu XZhang ZZhang YZhang XHe XYan HKe CfalseDevelopment of Receptor Binding Domain (RBD)-Conjugated Nanoparticle Vaccines with Broad Neutralization against SARS-CoV-2 Delta and Other Variants.The SARS-CoV-2 Delta (B.1.617.2) strain is a variant of concern (VOC) that has become the dominant strain worldwide in 2021. Its transmission capacity is approximately twice that of the original strain, with a shorter incubation period and higher viral load during infection. Importantly, the breakthrough infections of the Delta variant have continued to emerge in the first-generation vaccine recipients. There is thus an urgent need to develop a novel vaccine with SARS-CoV-2 variants as the major target. Here, receptor binding domain (RBD)-conjugated nanoparticle vaccines targeting the Delta variant, as well as the early and Beta/Gamma strains, are developed. Under both a single-dose and a prime-boost strategy, these RBD-conjugated nanoparticle vaccines induce the abundant neutralizing anti2022-01-01T00:00:00Z2022 Apr2025-04-05T00:40:03.296Z2024-11-15T17:04:57.924ZS-EPMC90087963514244410.1002/advs.202105378